Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 16, 2024 16:05 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

CARMEL, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
September 12, 2024 19:11 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Announces Pricing of Initial Public Offering

CARMEL, Ind., Sept. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
September 09, 2024 06:30 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Announces Launch of Initial Public Offering

CARMEL, Ind., Sept. 09, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision...
August 12, 2024 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Doses First Patient in Phase 2 Avail™ Trial of MBX 2109 for the Treatment of Hypoparathyroidism

CARMEL, Ind., Aug. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for...
August 05, 2024 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Raises $63.5 Million in Series C Financing to Advance Precision Endocrine Peptide™ (PEP™) Platform

Financing led by Deep Track Capital, with new investments from Driehaus Capital Management and funds and accounts advised by T. Rowe Price Associates, Inc. Proceeds to support ongoing Phase 2...
June 25, 2024 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Appoints Salomon Azoulay, M.D., as Chief Medical Officer

CARMEL, Ind., June 25, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for...
February 05, 2024 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Appoints Steven Ryder, M.D., to Board of Directors

CARMEL, Ind., Feb. 05, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical-stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
January 31, 2024 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
December 20, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Participate in 42nd Annual J.P. Morgan Healthcare Conference

CARMEL, Ind., Dec. 20, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
November 15, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Participate in Piper Sandler 35th Annual Healthcare Conference

CARMEL, Ind., Nov. 15, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right